Holen Sie sich die Stockscreener-App
323.02
1.31%
-4.29
Handel nachbörslich:
323.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$327.31
Offen:
$325.99
24-Stunden-Volumen:
372.40K
Relative Volume:
0.98
Marktkapitalisierung:
$7.13B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-12.86
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-1.75%
1M Leistung:
-8.16%
6M Leistung:
+33.59%
1J Leistung:
+18.33%
1-Tages-Spanne:
$321.27
$332.39
1-Wochen-Bereich:
$315.02
$344.17
52-Wochen-Spanne:
$189.00
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
323.02 | 7.13B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MyChesCo
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com
Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks
Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz
Madrigal Pharmaceuticals appoints new board member - Investing.com India
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times
Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com
Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com
Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World
Madrigal Pharmaceuticals CFO Mardi sells $637,247 in stock - Investing.com India
Madrigal Pharmaceuticals exec sells $418,488 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals exec sells $418,488 in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling - Defense World
B. Riley Analysts Increase Earnings Estimates for MDGL - Defense World
Sanctuary Advisors LLC Acquires 62 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
HC Wainwright Issues Negative Estimate for MDGL Earnings - Defense World
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $351.67 Consensus PT from Analysts - MarketBeat
New York State Common Retirement Fund Sells 5,630 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Citigroup Boosts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $469.00 - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock By Investing.com - Investing.com Australia
(MDGL) Trading Report - Stock Traders Daily
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock - Investing.com
Citigroup Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $405.00 Price Target at HC Wainwright - MarketBeat
B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236 - Marketscreener.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Strong Earnings - Defense World
Madrigal’s Earnings Call Highlights Strong Growth - TipRanks
Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP - TipRanks
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture? - Benzinga India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Quarterly Earnings Results, Beats Estimates By $1.61 EPS - MarketBeat
Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says - Marketscreener.com
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 - Investing.com India
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 By Investing.com - Investing.com UK
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highli - GuruFocus.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):